Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis - Top-Institutions - MDSpire

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis

  • By

  • Lei Liang

  • Bo Yang

  • Yuanyuan Wu

  • Jing-Lei Liu

  • Rongna Liu

  • Li Sun

  • July 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Clinica Universidad de Navarra
    Clinica Universidad de Navarra

    Pamplona, Navarra

    Key Differentiators

    • Oncology

  • #4

    Español de Investigación en Cáncer de Ovario
    Español de Investigación en Cáncer de Ovario

    Madrid, Madrid

    Key Differentiators

    • Oncology

  • #5

    Peking University People’s Hospital
    Peking University People’s Hospital

    Beijing, Beijing

    Key Differentiators

    • Oncology

Original Source(s)

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis

  • by Lei Liang, Bo Yang, Yuanyuan Wu, Jing-Lei Liu, Rongna Liu, Li Sun

  • July 9, 2026

Related Content

Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study says

Post-endoscopy gastric cancer in Latin America: a multicentre cohort study from Colombia

Case Report: Thoracic SMARCA4-deficient undifferentiated tumor with extraocular muscle metastasis: a rare case hidden in diplopia